{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:49:51Z","timestamp":1788432591656,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.soc.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T18:28:42Z","timestamp":1667500122000},"page":"83-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Past, Present, and Future Management of Localized Biliary Tract Malignancies"],"prefix":"10.1016","volume":"32","author":[{"given":"Janet","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio G.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.soc.2022.07.007_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2022.07.007_bib4","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.soc.2022.07.007_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1055-9965.EPI-15-0199","article-title":"Gallbladder Cancer Incidence and Mortality, United States 1999-2011","volume":"24","author":"Henley","year":"2015","journal-title":"Cancer Epidemiol biomarkers Prev"},{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/ejso.2001.1175","article-title":"Incidental carcinoma of the gallbladder","volume":"28","author":"Varshney","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2022.07.007_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jso.21141","article-title":"Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)","volume":"98","author":"Duffy","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jso.20537","article-title":"Management of cancer gallbladder found as a surprise on a resected gallbladder specimen","volume":"93","author":"Misra","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib9","first-page":"e3962","article-title":"Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.soc.2022.07.007_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","article-title":"Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?","volume":"40","author":"Shaib","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.soc.2022.07.007_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0002-9343(65)90178-6","article-title":"Adenocarcinoma of the Hepatic Duct at Its Bifurcation within the Porta Hepatis. An Unusual Tumor with Distinctive Clinical and Pathological Features","volume":"38","author":"Klatskin","year":"1965","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.soc.2022.07.007_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jso.26569","article-title":"Degree of biliary tract violation during treatment of gallbladder adenocarcinoma is independently associated with development of peritoneal carcinomatosis","volume":"124","author":"Sutton","year":"2021","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.07.007_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.soc.2022.07.007_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s11605-003-0029-5","article-title":"Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe","volume":"7","author":"Okami","year":"2003","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00000658-199201000-00005","article-title":"Management strategies in resection for hilar cholangiocarcinoma","volume":"215","author":"Bismuth","year":"1992","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/hpb.12444","article-title":"Gallbladder cancer: expert consensus statement","volume":"17","author":"Aloia","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"2","key":"10.1016\/j.soc.2022.07.007_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/SLA.0b013e318271497e","article-title":"The role of staging laparoscopy in primary gall bladder cancer--an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer","volume":"258","author":"Agarwal","year":"2013","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib18","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00268-011-1134-3","article-title":"Incidental gallbladder cancer by the AFC-GBC-2009 Study Group","volume":"35","author":"Fuks","year":"2011","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.soc.2022.07.007_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00534-009-0044-3","article-title":"Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study","volume":"16","author":"Araida","year":"2009","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.07.007_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1245\/s10434-008-0189-3","article-title":"Analysis of the extent of resection for adenocarcinoma of the gallbladder","volume":"16","author":"D'Angelica","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.07.007_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1245\/s10434-011-1850-9","article-title":"Is port site resection necessary in the surgical management of gallbladder cancer?","volume":"19","author":"Maker","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2022.07.007_bib22","series-title":"American Joint Committee on cancer (AJCC) staging Handbook: from the AJCC cancer staging Manual","author":"Edge","year":"2016"},{"issue":"2","key":"10.1016\/j.soc.2022.07.007_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/SLA.0b013e31822238d8","article-title":"Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment","volume":"254","author":"Ito","year":"2011","journal-title":"Ann Surg"},{"issue":"23","key":"10.1016\/j.soc.2022.07.007_bib24","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2022.07.007_bib25","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1245\/s10434-015-4472-9","article-title":"The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma","volume":"22","author":"Spolverato","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.07.007_bib26","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1097\/SLA.0000000000004137","article-title":"Response to the Comment on \"Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2022.07.007_bib27","doi-asserted-by":"crossref","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","article-title":"Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.07.007_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib29","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s11605-021-04910-9","article-title":"Anatomical Basis of Routine Caudate Lobe Resections in Hilar Cholangiocarcinoma","volume":"25","author":"Jain","year":"2021","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"114","key":"10.1016\/j.soc.2022.07.007_bib30","first-page":"321","article-title":"Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value?","volume":"59","author":"Wahab","year":"2012","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.soc.2022.07.007_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejso.2020.01.023","article-title":"A\u00a0systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma","volume":"46","author":"Birgin","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"10272","key":"10.1016\/j.soc.2022.07.007_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.soc.2022.07.007_bib34","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.07.007_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.soc.2022.07.007_bib36","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib37","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/cncr.11699","article-title":"Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies","volume":"98","author":"Jarnagin","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2022.07.007_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2016.05.019","article-title":"Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models","volume":"223","author":"Doussot","year":"2016","journal-title":"J\u00a0Am Coll Surg"},{"issue":"14","key":"10.1016\/j.soc.2022.07.007_bib39","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2022.07.007_bib40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.07.007_bib41","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.07.007_bib42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"24","key":"10.1016\/j.soc.2022.07.007_bib43","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.07.007_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11605-021-05143-6","article-title":"Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection","volume":"26","author":"Saluja","year":"2022","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.07.007_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jjco\/hyy004","article-title":"A\u00a0randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT)","volume":"48","author":"Nakachi","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.soc.2022.07.007_bib46","article-title":"Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT)","volume":"40","author":"Ikeda","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2022.07.007_bib48","author":"SK"},{"issue":"16_suppl","key":"10.1016\/j.soc.2022.07.007_bib49","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2022.40.16_suppl.4097","article-title":"NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine\/cisplatin\/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma","author":"Maithel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.07.007_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:04:46Z","timestamp":1760961886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1055320722000576"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.07.007","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, Present, and Future Management of Localized Biliary Tract Malignancies","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}